July, 2016

article thumbnail

Establishing a Solid Foundation for Digital Transformation

pharmaphorum

Sanofi Pasteur MSD is transforming its commercial organisation and remodeling its approach to customer engagement. Hear from Sanofi Pasteur MSD’s Alexandre Gultzgoff, Deputy Director, IT, and Antoine Blanc, Commercial Excellence Director, as they share first hand insights on how they are transforming their European commercial operations and improving customer engagement.

article thumbnail

Will Your Family Make You a Better Trial Participant?

Placebo Control

It is becoming increasing accepted within the research community that patient engagement leads to a host of positive outcomes – most importantly (at least practically speaking) improved clinical trial recruitment and retention. But while we can all agree that "patient engagement is good" in a highly general sense, we don't have much consensus on what the implications of that idea might be.

Trials 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What do the upcoming changes to England's pharmacy funding mean?

pharmaphorum

New measures proposed by the Government will impact community pharmacies across the UK; the biggest change of this nature in decades. The impact will go beyond community pharmacies as other stakeholders also feel the pressure. UK pharmacies already support more inhabitants per pharmacy than other major European markets; how will this funding change impact how patients are cared for in the community?

article thumbnail

BREXIT: What's next for pharma?

pharmaphorum

The pharmaceutical industry is one of the largest contributing industries to the UK’s balance of trade, and the UK Nation Health Service (NHS) is the fifth largest employer in the world. Although the process of exit for the UK from the EU has now to be triggered by invoking article 50, the post-Brexit calendar is a firestorm of uncertainty. The uncertainty could potentially have a chilling effect on global pharma investment in the UK, but are the issues that will impact Pharma - a jewel in the c

40
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

What's next for patient-centricity? How do we know when we are patient-centric?

pharmaphorum

This webinar will delve into the challenges that pharma face when looking at their patient-centricity strategy, and the opportunities that exist with this approach. We will explore the key motivators for this approach, and steps to overcome the internal and external barriers, and most importantly – how do pharma companies know when they have become truly patient-centric?